Voclosporin Success

Phase IIB Clinical Trial of Voclosporin Successfully Achieves Primary Endpoint

Good news posted yesterday on the Lupus Foundation of America website. To see the full article please click here.

“(Washington DC – August 15)  Today Aurinia Pharmaceutical Company announced positive top-line results of a Phase IIB clinical study of voclosporin, a potential new therapy option for people with active lupus nephritis (lupus-related kidney disease).  The study met its primary endpoint of achieving complete remission in a statistically significant number of study participants who received voclosporin. More details about this study are available through the company’s news release.

Survey on Access to Healthcare


EPF launches its survey on Access to Healthcare. This is a project that LUPUS EUROPE has been actively involved in as a participant in the Access to Healthcare work group at EPF.

Designed by patients and patient representatives, EPF launches a unique survey on access to healthcare. Share your experience on access and help us to design the EPF campaign on access to healthcare in 2017!

And don’t forget to share it with your network! The more replies we have the better; your input is vital evidence for EPF’s advocacy work on the topic!